EKSO
BEARISH
$8.73
Live
Ekso Bionics Holdings, Inc. · NASDAQ
Target $9.5
(+8.8%)
$2.73
52W Range
$13.5
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 09, 2026
Market cap
$31.11M
P/E
N/A
ROE
-107.6%
Profit margin
-91.4%
Debt/Equity
0.51
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
45%
EKSO shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
Key Strengths
Company has established market presence
Key Risks
Low profit margin of -91.4%
Weak financial trend (Piotroski F-Score: 1/9)
Declining revenue (-38.3%)
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
29
Weak
50
35
30
30
0
AI Verdict
EKSO shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
Key drivers: Company has established market presence, Low profit margin of -91.4%, Weak financial trend (Piotroski F-Score: 1/9)
Confidence
5%
Value
50/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Future
35/100
Rule-based growth outlook.
Positives
- Insufficient data for clear positives.
Watchpoints
- Revenue is contracting.
Past
30/100
Historical performance + price trend: Shares moved -91.1% over 5Y and +54.0% over 1Y.
Positives
- Insufficient data for clear positives.
Watchpoints
- ROE only -107.6%.
- Thin profit margins.
Health
30/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Dividend
0/100
Dividend policy fallback.
Positives
- Insufficient data for clear positives.
Watchpoints
- No regular dividend payments.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$8.73
Analyst Target
$9.5
Upside/Downside
+8.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for EKSO and closest competitors.
Updated 2026-04-08
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
EKSO
Ekso Bionics Holdings, Inc.
Primary
|
-91.1% | -64.0% | +54.0% | +66.6% | -27.2% | -18.0% |
|
BTAI
BioXcel Therapeutics, Inc.
Peer
|
-99.8% | -99.6% | -30.1% | -56.4% | -37.0% | -18.7% |
|
AYTU
Aytu BioPharma, Inc.
Peer
|
-98.4% | -24.2% | +61.7% | +2.7% | +6.7% | +1.5% |
|
DARE
Daré Bioscience, Inc.
Peer
|
-91.0% | -85.0% | -38.6% | -21.2% | +15.7% | -2.8% |
|
ATRA
Atara Biotherapeutics, Inc.
Peer
|
-98.9% | -95.6% | -24.7% | -54.9% | -70.3% | +15.0% |
EKS
Ekso Bionics Holdings, Inc.
Primary
5Y
-91.1%
3Y
-64.0%
1Y
+54.0%
6M
+66.6%
1M
-27.2%
1W
-18.0%
BTA
BioXcel Therapeutics, Inc.
Peer
5Y
-99.8%
3Y
-99.6%
1Y
-30.1%
6M
-56.4%
1M
-37.0%
1W
-18.7%
AYT
Aytu BioPharma, Inc.
Peer
5Y
-98.4%
3Y
-24.2%
1Y
+61.7%
6M
+2.7%
1M
+6.7%
1W
+1.5%
DAR
Daré Bioscience, Inc.
Peer
5Y
-91.0%
3Y
-85.0%
1Y
-38.6%
6M
-21.2%
1M
+15.7%
1W
-2.8%
ATR
Atara Biotherapeutics, Inc.
Peer
5Y
-98.9%
3Y
-95.6%
1Y
-24.7%
6M
-54.9%
1M
-70.3%
1W
+15.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-45.95
PEG Ratio
N/A
P/B Ratio
3.44
P/S Ratio
2.43
EV/Revenue
2.7
EV/EBITDA
-3.14
Market Cap
$31.11M
Profitability
Profit margins and return metrics
Profit Margin
-91.37%
Operating Margin
-119.71%
Gross Margin
53.48%
ROE
-107.62%
ROA
-33.62%
Growth
Revenue and earnings growth rates
Revenue Growth
-38.3%
Earnings Growth
N/A
Q/Q Revenue Growth
-38.31%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.51
Moderate
Current Ratio
1.63
Good
Quick Ratio
0.98
Poor
Cash/Share
$0.33
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
53.2%
Op. Margin
-143.6%
Net Margin
-148.9%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
1.23x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
103%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-04
$N/A
2026-02-23
$-1.56
-345.7% surprise
2025-10-28
$-0.54
+44.0% surprise
2025-07-28
$-1.24
+8.2% surprise
Healthcare Sector Comparison
Comparing EKSO against 189 companies in the Healthcare sector
(17 bullish, 63 neutral, 109 bearish)
Return on Equity (ROE)
-107.62%
This Stock
vs
-44.08%
Sector Avg
+144.1%
(Excellent)
Profit Margin
-91.37%
This Stock
vs
-19.57%
Sector Avg
+367.0%
(Superior)
Debt to Equity
0.51
This Stock
vs
5.1
Sector Avg
-89.9%
(Less Debt)
Revenue Growth
-38.3%
This Stock
vs
108.17%
Sector Avg
-135.4%
(Slower)
Current Ratio
1.63
This Stock
vs
3.39
Sector Avg
-52.0%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
EKSO
Ekso Bionics Holdings, Inc.
|
BEARISH | $31.11M | - | -107.6% | -91.4% | $8.73 | |
|
BTAI
BioXcel Therapeutics, Inc.
|
BEARISH | $29.51M | - | -% | -% | $1.09 | Compare |
|
AYTU
Aytu BioPharma, Inc.
|
NEUTRAL | $27.51M | - | -50.2% | -20.5% | $2.7 | Compare |
|
DARE
Daré Bioscience, Inc.
|
BEARISH | $25.77M | - | -% | -% | $1.77 | Compare |
|
ATRA
Atara Biotherapeutics, Inc.
|
BEARISH | $37.64M | 1.83 | -% | 15.4% | $5.22 | Compare |
EKSO
Ekso Bionics...
BEARISH
Mkt Cap
$31M
P/E
-
ROE
-107.6%
Price
$8.73
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-16 | JONES JASON C | Chief Operating Officer | Purchase | 1,308 | $15,500 |
| 2026-03-16 | WONG JEROME | Chief Financial Officer | Purchase | 1,308 | $15,500 |
| 2026-02-19 | ASHER DANIEL | Beneficial Owner of more than 10% of a Class of Security | Purchase | 1,200 | $14,760 |
| 2026-02-19 | ASHER DANIEL | Beneficial Owner of more than 10% of a Class of Security | Purchase | 15,540 | $191,162 |
| 2026-02-13 | ASHER DANIEL | Beneficial Owner of more than 10% of a Class of Security | Purchase | 102,029 | $970,069 |
| 2026-01-06 | JONES JASON C | Chief Operating Officer | Sale | 1,320 | $12,210 |
| 2025-12-09 | JONES JASON C | Chief Operating Officer | Sale | 270 | $1,269 |
| 2025-12-09 | WONG JEROME | Chief Financial Officer | Sale | 1,238 | $5,819 |
| 2025-11-10 | DAVIS SCOTT GERALD | Chief Executive Officer | Sale | 23,315 | $111,912 |
| 2025-11-10 | JONES JASON C | Chief Operating Officer | Sale | 9,723 | $46,670 |
| 2025-11-10 | WONG JEROME | Chief Financial Officer | Sale | 11,288 | $54,182 |
| 2025-11-05 | DAVIS SCOTT GERALD | Chief Executive Officer | Stock Award | 80,000 | - |
| 2025-11-05 | JONES JASON C | Chief Operating Officer | Stock Award | 15,000 | - |
| 2025-11-05 | WONG JEROME | Chief Financial Officer | Stock Award | 19,500 | - |
JONES JASON C
Chief Operating Officer
2026-03-16
1,308 shares
·
$15,500
WONG JEROME
Chief Financial Officer
2026-03-16
1,308 shares
·
$15,500
ASHER DANIEL
Beneficial Owner of more than 10% of a Class of Security
2026-02-19
1,200 shares
·
$14,760
ASHER DANIEL
Beneficial Owner of more than 10% of a Class of Security
2026-02-19
15,540 shares
·
$191,162
ASHER DANIEL
Beneficial Owner of more than 10% of a Class of Security
2026-02-13
102,029 shares
·
$970,069
JONES JASON C
Chief Operating Officer
2026-01-06
1,320 shares
·
$12,210
JONES JASON C
Chief Operating Officer
2025-12-09
270 shares
·
$1,269
WONG JEROME
Chief Financial Officer
2025-12-09
1,238 shares
·
$5,819
DAVIS SCOTT GERALD
Chief Executive Officer
2025-11-10
23,315 shares
·
$111,912
JONES JASON C
Chief Operating Officer
2025-11-10
9,723 shares
·
$46,670
WONG JEROME
Chief Financial Officer
2025-11-10
11,288 shares
·
$54,182
DAVIS SCOTT GERALD
Chief Executive Officer
2025-11-05
80,000 shares
JONES JASON C
Chief Operating Officer
2025-11-05
15,000 shares
WONG JEROME
Chief Financial Officer
2025-11-05
19,500 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
1 analysts
HC Wainwright & Co.
2025-12-31
Buy
Neutral
HC Wainwright & Co.
2025-11-18
Buy
Buy
Past News Coverage
Recent headlines mentioning EKSO from our newsroom.
Newest → oldest
No matching news yet.